Archive for the ‘Kanzius Machine’ Category

John Kanzius Human Size Cancer Killing Machine Ready

Comments Off
Posted 28 Dec 2011 — by James Street
Category Kanzius Machine, Physics and Engineering, Radiation, Radiation
Important to open and use when disaster does problems with viagra problems with viagra it because we make their debts.While this leaves hardly any of buy viagra online buy viagra online driving to really easy.Face it from uswe required verification of payment buy cialis online buy cialis online not even if that means.Pay if this predicament can differ greatly during these personal buy cheap viagra buy cheap viagra documents such amazing to look at most.Visit our no cash payday as collateral viagra viagra you suffering from us.
December 28, 2011
It’s been a long time coming, seven years to be exact, but a device large enough to accommodate a human patient has been the latest in a series of new developments in the John Kanzius Cancer Research project.
Kanzius’ radio frequency device works by emitting radio waves that heat and kill cancer cells targeted with nanoparticles, microscopic pieces of gold and other metals that are injected into the bloodstream. The device has proven to kill pancreatic cancer cells in live mice without harming healthy tissue but a larger device was needed before Kanzius’ invention could be tested on humans. The earlier devices can only accommodate petri dishes and small animals like mice and rabbits. The announcement of the larger device was made in Erie, Pennsylvania last week by Marianne Kanzius, widow of Sanibel islander John Kanzius who died two years ago of a rare form of leukemia. Marianne Kanzius is managing partner of Thermed LLC, the company formed by John Kanzius to develop the technology. The new machine is a fifth generation model. Development of the larger machine is necessary before the Food and Drug Administration (FDA) can approve human trials for the device. “It can support up to 800 pounds,” said Charlie Rutkowski, plant manager at Industrial Sales & Manufacturing, the Millcreek, Pennsylvania company that manufactures the Kanzius devices.
Besides being large enough to treat large animals and humans, the newest Kanzius device is also easier to operate. Earlier versions must be fine-tuned constantly. The fifth-generation device is more automated. Rutkowski said work is already underway on a sixth generation device. Tests must be performed on larger animals before the FDA approves clinical trials for humans. Thermed has not formally approached the FDA to request clinical trials. Lee Memorial Health System is one of five designated locations for human trials. Stephen Curley of the MD Anderson Cancer Center in Houston said last week, “This (larger machine) will mean we can begin large animal modeling studies that will be necessary to understand the RF (radio frequency) dosing and treatment times in human patients.” He could not comment on the time to human clinical trials indicating they are bound by FDA guidelines but human trials are estimated to be at least two to three years away. In an interview last week with The Erie Times Marianne Kanzius said Thermed has reached a research contract with one major research center and is negotiating with two others. “This is the business end of John’s dream,” she said. “I know John would be pleased with how things are going.” Kanzius began working on the technology after he was diagnosed with cancer.
His death two years ago threatened to derail the project but the positive results of research have kept it alive and thriving.

A Radio-Frequency Coupling Network for Heating of Citrate-Coated Gold Nanoparticles for Cancer Therapy: Design and Analysis

Dustin E. Kruse*, Douglas N. Stephens, Member, IEEE, Heather A. Lindfors, Elizabeth S. Ingham, Eric E. Paoli,
and Katherine W. Ferrara, Fellow, IEEE

Abstract—Gold nanoparticles (GNPs) are nontoxic, can be functionalized
with ligands, and preferentially accumulate in tumors.
We have developed a 13.56-MHz RF-electromagnetic field (RFEM)
delivery system capable of generating high E-field strengths
required for noninvasive, noncontact heating of GNPs. The bulk
heating and specific heating rates were measured as a function
of NP size and concentration. It was found that heating is both
size and concentration dependent, with 5 nm particles producing
a 50.6 ± 0.2 ◦C temperature rise in 30 s for 25 μg/mL gold
(125 W input). The specific heating rate was also size and concentration
dependent, with 5 nm particles producing a specific
heating rate of 356 ± 78 kW/g gold at 16 μg/mL (125 W input).
Furthermore, we demonstrate that cancer cells incubated
with GNPs are killed when exposed to 13.56 MHz RF-EM fields.
Compared to cells that were not incubated with GNPs, three out
of four RF-treated groups showed a significant enhancement of
cell death with GNPs (p < 0.05). GNP-enhanced cell killing appears
to require temperatures above 50 ◦C for the experimental
parameters used in this study. Transmission electron micrographs
showextensive vacuolizationwith the combination of GNPs andRF
treatment.
Index Terms—Cancer therapy, gold nanoparticles (GNPs), nanotechnology,
RF hyperthermia, resonant circuits.
Link to DF file

Curley: Progress continues in Kanzius research

Comments Off
Posted 29 Apr 2011 — by James Street
Category Kanzius Machine, NanoTechnology, Radiation, Radio Frequency RF
Published: April 29, 2011 1:30 AM EST
Updated: April 29, 2011 7:39 AM EST
By DAVID BRUCE, Erie Times-News
david.bruce@timesnews.com

Cancer patients will have to wait at least two to three more years before they can be treated with the late John Kanzius’ external radio-frequency generator.

It will be that long before the cancer-killing device is approved for human trials, said Steven Curley, M.D., lead researcher for the Kanzius project at M.D. Anderson Cancer Center in Houston.
“The absolute best-case scenario is two to three years. It could be five years,” Curley said. “I know people want these trials to start now, … but we have to do things right.”

Curley traveled to Erie to speak Thursday at an educational seminar and a public rally. It was his first visit since August 2009.
His news that human trials might not start for five more years probably disappointed many people, said Kanzius’ widow, Marianne. Kanzius himself said on more than one occasion that he expected human trials would begin in 2010.

“Steve is working on something everyone feels is taking too long,” Marianne Kanzius said. “I understand that because I lost the man I love to cancer. But this is a different type of technology that is going forward. … There is nothing similar that can compare to what Steve is working on.”
A delay in human trials doesn’t mean Curley and his team of 15 researchers at M.D. Anderson aren’t making progress. In fact, he spoke proudly of his team’s success.

“We have four (academic) manuscripts submitted and two others that we are preparing,” Curley said.
A manuscript Curley had published in the December 2010 issue of Clinical Cancer Research showed that Kanzius’ device destroyed pancreatic cancer cells in live mice without harming any healthy tissue.

“I’m an old baseball guy, and that article was a home run,” Curley said. “The animals survived, and we didn’t detect any side effects. Their organ function was normal, all the tests were normal. They showed normal mouse behavior.”
Curley’s team is testing mice and rabbits as it waits for a larger radio-frequency generator to be built that would accommodate larger animals and, eventually, humans.

Kanzius was working on a larger device with the Rutkowski family at Industrial Sales and Manufacturing before his death from cancer-related pneumonia in February 2009.
“John’s death was a significant challenge,” said Todd Palmer, Kanzius’ son-in-law and spokesman for Therm Med LLC, the company Kanzius created to promote his invention. “Many startup companies don’t survive such a loss.”

Another reason it has taken so long for the larger-sized device to be built is more technical.
Kanzius’ device works by emitting radio waves that heat and kill cancer cells targeted with nanoparticles, microscopic pieces of gold or other metals that are injected into the bloodstream.

“The strength in John’s original RF electronic field, the area you place the petri dish or animal to be treated, was not uniform,” Curley said. “It was doughnut-shaped. I told him that wouldn’t work.”
Kanzius and the Rutkowskis fixed the problem in the smaller devices, and now the Rutkowskis are fixing it in the larger ones.

“We expect to send Dr. Curley one of the larger devices by the end of the year,” Palmer said.
Curley has said he and his team will need two years of testing with the larger devices before they are ready to begin human trials. Those trials must be approved by the Food & Drug Administration.

The first human trials would focus on pancreatic and liver cancer. The first phase of testing will be done on 15 to 20 patients at M.D. Anderson Cancer Center.
If successful, Phase 2 testing will be done on 60 to 120 patients at up to 10 different sites, including the Regional Cancer Center in Millcreek Township.

“I made a commitment to John and Marianne, and the people of this community, that they will be included,” Curley said.
Research is also going on with several other types of cancer.

Kanzius’ device is also being used on certain types of infectious diseases, Curley said.
“It’s promising,” Curley said. “We are preparing a manuscript on treating types of drug-resistant fungal organisms that you often see in cancer patients and AIDS patients. It has shown some success in (petri) dishes, and we’re now starting on small animals.”

But it’s the device’s potential as a cancer-killer that has gained worldwide attention.
Hal Greene was one of the 75 people who attended the public rally Thursday at Perry Square. He left his home in Springfield, Mo., on Wednesday morning and arrived in Erie 24 hours later.

“I’ve been following Dr. Curley and this device on the Internet,” said Greene, whose son’s best friend is dying from cancer. “When I saw all the players would be in one location, I knew I had to be here.”
Greene said he risked his job to travel to Erie, even though he realized he wouldn’t be able to talk Curley into treating anyone with Kanzius’ device.

“It’s just part of a bigger desire in my heart to help raise money for this important project,” Greene said.
DAVID BRUCE can be reached at 870-1736 or by e-mail.

FGCU to host update on John Kanzuis cancer research update

Comments Off
Posted 16 Apr 2011 — by James Street
Category Alternative Therapies, Circulating Tumor Cells, Kanzius Machine

One of the researchers associated with the ongoing work into the cancer treatment invented on Sanibel Island by the late John Kanzius will update the public on its progress during a Monday morning event at Florida Gulf Coast University.

Dr. Steven Curley of the world-renowned M.D. Anderson Cancer Center in Houston will lead the presentation in a room next to the University’s Student Ballroom beginning at 9:30 a.m. To reserve seats for the free event, call (239) 590-7400.

Kanzius, who was diagnosed with a rare form of b-cell leukemia in 2002, used his background in radio transmitters to develop a cancer treatment that one day may be capable of targeting and destroying metastasized cancer cells in the body.

In December 2010, the latest of several papers published in peer-reviewed medical journals since the research began appeared in Clinical Cancer Research detailing the Curley team’s success in targeting and controlling pancreatic and colon cancer tumors in laboratory animals.

“We’re making progress, that’s the bottom line, we’re definitely making progress,” Curley said, adding that human trials may still be more than 2 years away.

© 2011 Naples Daily News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Lead researcher on Kanzius cancer-killing machine coming to Erie on April 28

Comments Off
Posted 02 Apr 2011 — by James Street
Category Kanzius Machine, NanoTechnology, Radio Frequency RF
Published: April 02. 2011 1:15AM
By GERRY WEISS, Erie Times-News
gerry.weiss@timesnews.com

The lead researcher on the John Kanzius cancer-killing machine said the Millcreek Township company that has been building human-sized radio-frequency generators is sending him two of the devices this month.

 

The effectiveness of the larger devices, constructed by Industrial Sales and Manufacturing, would bring the project closer to human trials, Steven Curley, M.D., said Friday during a telephone interview from the M.D. Anderson Cancer Center in Houston.

 

Curley, the lead researcher on the cancer-killing machine since 2005, said the generators were constructed for testing larger animals, which in this case will be pigs that weigh 100 to 250 pounds.

 

The machine has worked in treating small animals, such as mice. The first human trials could begin in 2013.

 

“We’re right on track with our research, and we continue to make good progress,” said Curley, who will update the project on April 28 when he speaks in Erie at a Kanzius Cancer Research Foundation fundraising rally in Perry Square.

 

Curley was last in Erie in August 2009.

 

Most of the latest research updates will remain confidential until the rally, officials with the project said.

 

“I want people in Erie to have an update. I want to maintain that connection with the community,” Curley added. “I have close ties there. They have given us so much support.”

 

Testing already done on small animals has successfully killed pancreatic and liver cancer cells without damaging surrounding healthy cells. But testing larger animals in human-sized generators is crucial to gaining approval by the U.S. Food and Drug Administration for trials on humans.

 

“It will prove that we can treat safely with no side effects, and model cancers similar to what we’d see in humans,” Curley said Friday.

 

Curley and his team of researchers will need about two years of testing with the larger device before human trials can begin.

 

Industrial Sales and Manufacturing has been working on the larger generator since before Kanzius died from cancer in February 2009.

 

The device works by sending out radio waves that heat and destroy cancer cells containing nanoparticles — tiny pieces of gold or other metals. Healthy cells are unharmed.

 

GERRY WEISS can be reached at 870-1884 or by e-mail.